- Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface
-
Rational designs of small-molecule inhibitors targeting protein-protein interfaces have met little success. Herein, we have designed a series of triazole derivatives with a novel scaffold to specifically intervene with the interaction of TLR8 homomerization. In multiple assays, TH1027 was identified as a highly potent and specific inhibitor of TLR8. A successful solution of the X-ray crystal structure of TLR8 in complex with TH1027 provided an in-depth mechanistic insight into its binding mode, validating that TH1027 was located between two TLR8 monomers and recognized as an unconventional pocket, thereby preventing TLR8 from activation. Further biological evaluations showed that TH1027 dose-dependently suppressed the TLR8-mediated inflammatory responses in both human monocyte cell lines, peripheral blood mononuclear cells, and rheumatoid arthritis patient specimens, suggesting a strong therapeutic potential against autoimmune diseases.
- Jiang, Shuangshuang,Tanji, Hiromi,Yin, Kejun,Zhang, Shuting,Sakaniwa, Kentaro,Huang, Jian,Yang, Yi,Li, Jing,Ohto, Umeharu,Shimizu, Toshiyuki,Yin, Hang
-
p. 4117 - 4132
(2020/05/22)
-
- SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
-
In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R1, n, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
- -
-
Page/Page column 58; 66-67
(2020/06/10)
-
- OXADIAZOLE LINKERS AND USE THEREOF
-
Provided is oxadiazole linkers and use thereof, more specifically to the compounds represented by formulas (I), (II), and (III), and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from said oxadiazole linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula (I), (II), and (III) is the same as that in the description.
- -
-
Page/Page column 38; 43
(2019/01/30)
-
- Discovery of a flexible triazolylbutanoic acid as a highly potent uric acid transporter 1 (URAT1) inhibitor
-
In order to systematically explore and understand the structure-activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a-1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 μM against human URAT1 for 1q vs. 7.18 μM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.
- Tian, He,Liu, Wei,Zhou, Zhixing,Shang, Qian,Liu, Yuqiang,Xie, Yafei,Liu, Changying,Xu, Weiren,Tang, Lida,Wang, Jianwu,Zhao, Guilong
-
-
- HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.
- -
-
Paragraph 0121
(2014/07/21)
-
- HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
- -
-
Paragraph 0113
(2014/07/21)
-
- HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER
-
Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.
- -
-
Page/Page column 42
(2014/07/21)
-
- Preparation and Thermolysis of N-Ammonioamidates Containing Hydroxyl Group in Acyl Moiety
-
The title ammonioamidates (aminimides) were prepared in satisfactory yields from lactones or α-hydroxy carboxylates.By the thermolysis of these aminimides in mesitylene, some types of urethane compounds were formed, depending on the structure of the aminimide and on the concentration of the solutions.
- Masuyama, Araki,Tsuchiya, Kikuo,Okahara, Mitsuo
-
p. 2855 - 2859
(2007/10/02)
-
